Premium
6‐month buprenorphine implant approved
Publication year - 2016
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30143
Subject(s) - buprenorphine , food and drug administration , medicine , implant , opioid , drug , anesthesia , psychiatry , pharmacology , surgery , receptor
In May, the Food and Drug Administration approved Probuphine, the first buprenorphine implant for treatment of opioid dependence. “The safety and effectiveness of Probuphine have not been established in children or adolescents < 16 years of age,” according to the labeling.